3. When can clinical response to TNF-α inhibitors be observed in RA patients?
Anonymous Quiz
8%
a. Within 24 hours
10%
b. Within 1 week
66%
c. Within 2 weeks
6%
d. Within 1 month
9%
e. After 3 months
4. What caution should be taken when using TNF-α inhibitors in patients with heart failure?
Anonymous Quiz
5%
a. No caution needed
28%
b. Decrease in dosage
52%
c. Avoidance due to toxicity
3%
d. Increase in dosage
12%
e. Preferential use in heart failure
💔4
5. What risk is associated with the use of TNF-α inhibitors and non-TNF biologic agents together?
Anonymous Quiz
9%
a. Joint damage improvement
20%
b. Increased risk of lymphoma
2%
c. Enhanced clinical response
67%
d. Severe infections
3%
e. Reduced side effects
💔3
6. How does adalimumab interfere with TNF-α activity?
Anonymous Quiz
3%
a. Enhances its binding to receptors
89%
b. Blocks its interaction with cell surface receptors
5%
c. Promotes its synthesis
2%
d. Increases TNF-α production
1%
e. Induces TNF-α degradation
7. What is the administration frequency of adalimumab?
Anonymous Quiz
7%
a. Daily
7%
b. Every other day
81%
c. Weekly
5%
d. Monthly
0%
e. Annually
8. What distinguishes certolizumab from other TNF-α inhibitors?
Anonymous Quiz
3%
a. Increased injection frequency
14%
b. Lower risk of infections
77%
c. Combined with pegylated substance
4%
d. Oral administration
2%
e. No adverse effects
9. How often is certolizumab administered?
Anonymous Quiz
9%
a. Weekly
8%
b. Monthly
77%
c. Every 2 weeks
5%
d. Every 3 months
1%
e. Twice daily
10. What is the mechanism of action of etanercept?
Anonymous Quiz
4%
a. Enhances TNF-α synthesis
82%
b. Blocks TNF-α receptors
6%
c. Induces TNF-α degradation
4%
d. Promotes TNF-α release
4%
e. Stimulates TNF-α production
11. How does golimumab neutralize TNF-α activity?
Anonymous Quiz
4%
a. Inducing TNF-α production
4%
b. Enhancing TNF-α receptors
81%
c. Blocking interaction with cell surface receptors
1%
d. Stimulating TNF-α release
10%
e. Binding to CD80/CD86 protein
12. What is the administration frequency of golimumab?
Anonymous Quiz
9%
a. Every 2 weeks
67%
b. Once a month
6%
c. Twice daily
8%
d. Every 8 weeks
9%
e. Every 4 weeks
13. What is the composition of infliximab, a chimeric monoclonal antibody?
Anonymous Quiz
3%
a. Fully human
11%
b. Murine
82%
c. Human and murine regions
1%
d. Rat-derived
2%
e. Synthetic
14. Why is infliximab not indicated for monotherapy in RA?
Anonymous Quiz
4%
a. Increased efficacy
2%
b. Reduced infusion reactions
81%
c. Development of anti-infliximab antibodies
8%
d. Improved B-cell depletion
4%
e. Prevention of TNF-α binding
15. How does abatacept modulate T cell activation?
Anonymous Quiz
4%
a. Enhances CD28 binding
10%
b. Stimulates CD80/CD86 production
85%
c. Competes with CD28 for binding on CD80/CD86 protein
1%
d. Induces B-cell depletion
0%
e. Increases TNF-α release
16. What is the common frequency of abatacept administration?
Anonymous Quiz
9%
a. Every 2 weeks
5%
b. Once a month
65%
c. Every 4 weeks
17%
d. Every 8 weeks
3%
e. Twice daily
17. What is the primary target of rituximab in RA?
Anonymous Quiz
12%
a. T lymphocytes
5%
b. TNF-α receptors
70%
c. CD20 antigen on B lymphocytes
12%
d. IL-6 receptors
1%
e. CD28 protein
18. What is administered prior to rituximab infusion to reduce reactions?
Anonymous Quiz
40%
a. Acetaminophen
9%
b. NSAIDs
8%
c. Antibiotics
42%
d. Corticosteroids
0%
e. Antifungals
✨طريقك نحو الرسوب✨
18. What is administered prior to rituximab infusion to reduce reactions?
هنا حسب الملزمة المفروض a
❤🔥3❤1
19. What is the primary target of tocilizumab and sarilumab?
Anonymous Quiz
6%
a. TNF-α
8%
b. IL-1
78%
c. IL-6 receptors
6%
d. CD20 antigen
3%
e. CD28 protein
21. What is the primary target of tofacitinib in the treatment of RA?
Anonymous Quiz
1%
a. Interferon-alpha
12%
b. Tumor necrosis factor (TNF)
17%
c. Interleukin-6 (IL-6)
68%
d. Janus kinases
1%
e. CD20 antigen
22. When is tofacitinib typically reserved for RA treatment?
Anonymous Quiz
7%
a. First-line therapy
63%
b. Intolerance to other agents
16%
c. Only in severe RA cases
7%
d. Long-term prevention
7%
e. As monotherapy